Targeted epigenetic induction of mitochondrial biogenesis enhances antitumor immunity in mouse model

Area of Science:

• Immunology
• Molecular Biology
• Cancer Research

Background:

• Cancer immunotherapy faces limitations, necessitating novel combinatorial approaches.
• Existing epigenetic drugs lack sequence specificity, posing challenges for targeted therapy.
• Programmed cell death protein 1 (PD-1) blockade is a key immunotherapy strategy requiring augmentation.

Purpose of the Study:

• To identify and develop small-molecule modulators of immune cells to enhance PD-1 blockade therapy.
• To investigate a novel DNA-based epigenetic activator, EnPGC-1, for targeted induction of PGC-1α/β.
• To evaluate the efficacy of EnPGC-1 in enhancing T-cell function and antitumor immunity.

Main Methods:

• Development of a DNA-based epigenetic activator (EnPGC-1) with a tri-arginine vector.
• In vitro assessment of EnPGC-1's effects on mitochondrial activation, energy metabolism, and CD8+ T-cell proliferation.
• Genome-wide gene expression analysis to identify biological processes regulated by EnPGC-1.
• In vivo evaluation of EnPGC-1 in combination with PD-1 blockade for antitumor immunity.

Main Results:

• EnPGC-1 successfully triggered targeted induction of PGC-1α/β.
• EnPGC-1 enhanced mitochondrial activation, energy metabolism, and CD8+ T-cell proliferation, particularly oxidative phosphorylation.
• Genome-wide analysis confirmed EnPGC-1's regulation of T-cell activation.
• EnPGC-1 synergized with PD-1 blockade, significantly enhancing antitumor immunity and host survival.

Conclusions:

• EnPGC-1 is a potent DNA-based epigenetic activator that enhances T-cell function.
• The combination of EnPGC-1 and PD-1 blockade represents a promising strategy for improving cancer immunotherapy outcomes.
• Targeted induction of PGC-1α/β via EnPGC-1 offers a novel approach to augment antitumor responses.